Bio Essence

Bio Essence Financing Cash Flow

The Net Financing Cash Flow of Bio Essence (BIOE) as of Nov 5, 2026 is -1.57 M USD. In the previous year, Net Financing Cash Flow was -622,494.00 USD — a change of 152.39% (lower).

Financing Cash Flow

-1.57 MUSD

YoY

152.39%

Last updated:

Net Financing Cash Flow of Bio Essence is 2025 -1.57 M USD. Net Financing Cash Flow of Bio Essence was 2024 -622,494.00 USD. It decreases by 152.39% lower compared to the previous year.

The Bio Essence Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
206,376.00 USD
Jan 1, 2019
931,063.00 USD
Jan 1, 2020
729,273.00 USD
Jan 1, 2021
1.41 M USD
Jan 1, 2022
768,320.00 USD
Jan 1, 2023
1.11 M USD
Jan 1, 2024
-622,494.00 USD
Jan 1, 2025
-1.57 M USD
The Bio Essence Financing Cash Flow history
YEARFinancing Cash FlowYoY
-1.57 MUSD+152.39%
-622,494.00USD-156.03%
1.11 MUSD+44.60%
768,320.00USD-45.35%
1.41 MUSD+92.78%
729,273.00USD-21.67%
931,063.00USD+351.15%
206,376.00USD-92.72%
2.84 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Essence Stock analysis

What does Bio Essence do? Bio Essence Corp. generates revenue through its three subsidiaries: Bio Essence Pharmaceutical (BEP), which operates as a health supplement original equipment manufacturer (OEM) service provider; Bio Essence Herbal Essentials (BEH), which targets healthcare practitioners with herbal products including granules, capsules, pills, and tablets, and offers special formulation services; and McBE Pharma (McBE), which develops, manufactures, and sells prescription drugs. The company's products are sold directly to healthcare practitioners such as dietitians and nutraceutical practitioners, who then recommend them to their patients. BEH specifically serves practitioners in the integrative healthcare market, providing both standard and custom-formulated herbal supplements. BEP functions as an OEM for health supplement manufacturers, producing private-label products under other brands. McBE Pharma focuses on prescription drugs, targeting healthcare providers for direct sales. The firm's direct connections with practitioners enable it to reach end consumers through professional recommendations rather than retail channels. Bio Essence Herbal Essentials Inc. (BEH) emphasizes its role in connecting practitioners with patients through tailored herbal supplement solutions. The company's revenue streams are derived from the sale of herbal health supplements, vitamin nutritional supplements, and prescription drugs. BEH's target segment includes practitioners who specialize in integrative healthcare, such as dietitians and nutraceutical practitioners, who use the company's products to support patient care. McBE Pharma's segment consists of healthcare providers seeking prescription drug solutions for their patients. BEP serves as a manufacturing partner for other supplement brands, supplying OEM services. Bio Essence is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Essence stock

Net Financing Cash Flow of Bio Essence is -1.57 M USD in 2025.

Net Financing Cash Flow of Bio Essence changed from -622,494.00 USD to -1.57 M USD, representing a 152.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Bio Essence since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Bio Essence historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Essence

All Key Metrics — Bio Essence